Latest "Mifepristone Cushing Syndrome" News Stories

US FDA panel to weigh efficacy, safety of Novartis Cushing's drug

On the same day last February California-based Corcept Therapeutics' Korlym (mifepristone), a cortisol receptor blocker, won approval by the US FDA as the first treatment in the US for patients with Cushing's syndrome, a rare and life-threatening......

FDA panel unanimously backs Novartis' pasireotide

FDA's Endocrinologic and Metabolic Drugs Advisory committee voted 10-0 that efficacy and safety data for pasireotide from Novartis AG (NYSE:NVS; SIX:NOVN) support approval to treat Cushing's disease. Novartis submitted the application on Feb. 17 and...

Corcept trades GR-II antagonist royalties for non-dilutive cash from Pharmakon

Corcept Therapeutics has sold a total of $45 million worth of royalties for the recently launched Cushing's syndrome drug Korlym (mifepristone 300mg tablets) and any of its next-generation drugs in the same GR-II antagonist class to Pharmakon Advisor...

Corcept Begins Recovery After Disastrous Launch Of Korlym

By Brian L. Wilson:Last year, the drug developer Corcept Therapeutics (NASDAQ: CORT) received FDA approval for its flagship product Korlym (mifepristone) for the treatment of Cushing's syndrome.Investors were initially ecstatic about the drug's approval, since it was the only drug available for Cushing's Syndrome patients that would be on the market. It's also worth noting that Korlym was granted...

Steroid induced Cushing’s warning

People who develop Cushing’s syndrome as a result of taking systemic glucocorticoids are at very high risk of cardiovascular disease, warn researchers.

Cushing’s patients must be screened for heart disease

Individuals who use glucocorticoids and exhibit iatrogenic Cushing’s syndrome should be “aggressively” targeted for early screening of cardiovascular risk factors, say researchers.

MR Brain Spectroscopy Detects Damage In The Hippocampus Of Patients Exposed To Excess Cortisol

New research shows that patients who are "biochemically cured" of Cushing's syndrome have levels of brain metabolites which are associated with neural damage. This will have implications for treatment of Cushing's patients, but might also suggest tha...

Corcept raises $46.4 million

Corcept Therapeutics Inc. (NASDAQ:CORT) raised $46.4 million late Friday through the sale of 11 million shares at $4.22 in a follow-on underwritten by Credit Suisse. Corcept proposed the offering on July 2, when its share price was $4.49. On Monday,...

Corcept planning follow-on

Corcept Therapeutics Inc. (NASDAQ:CORT) proposed to sell 11 million shares in a follow-on underwritten by Credit Suisse. If sold at the Corcept's Friday close of $4.49, the company would raise $49.4 million. Corcept was off $0.21 to $4.28 on Monday....

FDA posts pasireotide briefing documents

FDA reviewers said pasireotide from Novartis AG (NYSE:NVS; SIX:NOVN) is effective for treating Cushing's disease, but cautioned that the "efficacy results need to be considered in the context of the overall safety profile" of the somatostatin analog....

Novartis’ Signifor Seeks Controlled-Data Edge In Cushing Market At Advisory Committee

Cushing’s disease treatment Signifor (pasireotide) underwent a randomized Phase III clinical trial, while the earlier approval of competitor Corcept Therapeutics’ Korlym (mifepristone) was based on an open-label study.

Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study

Objective To investigate whether there is an increased risk of cardiovascular events in people who exhibit iatrogenic Cushing’s syndrome during treatment with glucocorticoids.Design Cohort...

Corcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference Call

MENLO PARK, CA -- (Marketwired) -- 04/26/13 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter 2013 financial results on May 2, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internation...

ECE: Abnormal metabolites found in cured cushing's patients

(HealthDay)—Patients with Cushing's syndrome have abnormal brain metabolites suggestive of neuronal dysfunction even after they appeared to have been cured, according to a study presented at the annual European Congress of Endocrinology, held from...

Pharmakon-affiliated fund pays [Corcept] $30mm in royalty financing

Just one month after completing a $46.1mm follow-on public offering, [Corcept Therapeutics Inc.] (medicines that regulate the hormone cortisol) is raising funds again, this time through a royalty financing. In exchange for $30mm, Corcept has sold to...

FDA approves Novartis' Signifor for Cushing's

FDA approved late Friday an NDA from Novartis AG (NYSE:NVS; SIX:NOVN) for Signifor pasireotide to treat Cushing's disease when surgery is not an option or has failed. As part of the approval, the pharma is required to conduct three postmarketing stud...

Therapy: Glucocorticoid-induced Cushing syndrome increases the risk of cardiovascular events

Medical Management of Cushing's Syndrome

Medications used for Cushing disease include an antifungal, anticonvulsant, and dopamine agonist. Expert Review of Endocrinology and Metabolism

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease

Novartis announced that the US Food and Drug Administration (FDA) has approved Signifor® (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative3. Signif...

Cushing syndrome

Cushing syndrome — Comprehensive overview covers symptoms, treatment of this disorder caused by excess cortisol.

Corcept in $30M royalty deal

Corcept Therapeutics Inc. (NASDAQ:CORT) granted a Pharmakon Advisors fund rights to receive up to $45 million in royalties on Corcept's products in exchange for $30 million in cash. In April, Corcept launched Korlym mifepristone -- its first marketed...

FDA approves new orphan drug for Cushing’s disease

Novartis’ Signifor injection has been approved to treat patients in the United States who have the serious, debilitating endocrine disorder, Cushing’s disease. The US FDA has approved a new orphan drug to treat patients with Cushing’s disease...

Cushing's disease drug from Novartis gets FDA nod

Novartis obtained FDA approval for Signifor, or pasireotide, to treat patients with Cushing's disease who can't have surgery  -More- 

FDA Reviewers Call Cushing Drug Effective

WASHINGTON (MedPage Today) -- A new product appears to effectively treat Cushing's disease, although the FDA is raising some questions in advance of a panel meeting to vote on recommending its approval.

Tuebingen Cushing's Disease QOL Inventory: Part II

Can this QOL instrument provide comparative data in studies evaluating patients with Cushing's disease? Clinical Endocrinology